Aurobindo Pharma's Telangana Facility Receives 10 Observations from USFDA
The USFDA has issued 10 observations to Aurobindo Pharma's API manufacturing unit in Telangana after a September 2024 inspection. The procedural observations will be addressed within the stipulated time. Shares of the company fell by 3.16% on the BSE following the news.
- Country:
- India
The US health regulator has raised 10 procedural observations following an inspection of Aurobindo Pharma's API manufacturing facility in Telangana.
The US Food and Drug Administration (USFDA) conducted the inspection from September 23-27, 2024, at Unit-II, an active pharmaceutical ingredients plant owned by Apitoria Pharma, a wholly-owned subsidiary of Aurobindo Pharma.
The company has confirmed that these observations are procedural and will be addressed within the stipulated period. Following the announcement, Aurobindo Pharma's shares dropped by 3.16% to Rs 1,462 apiece on the BSE.
Google News